Skip to Main Content

Go to Main Navigation


Year Established:
Barcelona, Catalonia, ES
Company Type:
Small Business (1-10M TTM Revenue)

Enantia provides chemical services in the fields of medicinal chemistry, process R&D, custom synthesis and crystal engineering.

Enantia is a leader in cocrystallization technologies and chiral chemistry. Enantia develops chemical and solid state technologies for the fine chemicals and pharmaceutical sectors. The company can contribute all the way from initial research in medicinal chemistry or route scouting to any phase of process R&D. Enantia’s unique approach allows for creative and innovative solutions which make possible the most challenging projects.

Enantia’s Medicinal Chemistry team is composed of experienced medicinal and synthetic chemists used to dealing with challenging targets and projects, such as the ones involving asymmetric chemistry to render 3D-shaped small molecules or just to introduce a chiral centre that can be key to achieve target selectivity.

We synthesize, collaborating in the design when needed, focused libraries of new compounds or interesting scaffolds to carry out programs of drug discovery, covering hit finding, hit to lead and lead optimization to preclinical candidate.

We can also prepare cold labelled compounds, standards and metabolites needed during the preclinical phase of the drug development.

In our chemical RD department, we develop new routes of synthesis to be scaled-up and optimize chemical steps of current synthetic routes following our client’s requirements (yield, cost, etc.).

We can also do impurity profiling and carry-over of a specific route of synthesis, as well as prepare new impurities that arise during stability testing and formulation of a given API.

We tackle almost any type of projects, and we are particularly comfortable working on chiral molecules, especially when they need to be prepared in an enantiomerically pure form or resolved from complex mixtures.

In addition, we can custom synthesize almost any compound up to kilo-lab in house. In this sense, we count with a new kilo-lab facility with a 15L jacketed reactor plus ancillary equipment.

Enantia performs solid form screenings to find the best solid form of a given molecule.
We study the different salts, polymorphs and cocrystals (and also solvates and hydrates if it is needed) that a compound (or a combination of them) can have.

Furthermore, we count with a spray dryer (Mini Spray Dryer B-290 de Büchi) which can work with aqueous solutions and organic solvents, to perform amorphous form development.
The different solid forms of a compound can modify several physicochemical properties of a given compound (solubility, light and thermal stability, rheology, etc.) allowing for example to transform an oily or liquid compound into a solid or to increase its bioavailability. Furthermore, solid forms are a good tool to increase the IP protection of a given molecule.

Besides their applications to improve the physicochemical properties of a given compound and increase its IP protection, we also use cocrystallization technology to generate easy, efficient and scalable processes to purify and resolve compounds from complex mixtures. This is specially interesting when facing a purification or resolution that is technically very difficult or has an important economic impact. We usually apply this technology to avoid the use more expensive and time-consuming techniques such as chromatography, usually needed when the compounds cannot be purified through standard crystallization or when salt formation is not an option or not rendering good results.

Enantia counts with a Solid Form Analysis department that offers services analysing APIs and excipients alone or in drug products, especially when developing new formulations or when problems appear during manufacturing, such as differences in two batches regarding properties like solubility or stability.

We offer X-Ray, electronic microscopy, atomic forces microscopy, DVS, DSC, PSD and TGA among others for a really detailed understanding of the solid-state during drug development and manufacturing.

We can also detect and quantify crystalline infringing forms of an API in a given matrix. For this, we can either use our own X-Ray diffractometer or use Synchrotron radiation, especially when the % of the form to be detected is very low, therefore very high sensitivity is needed. In this sense, Synchrotron X-Ray radiation is much more sensitive than a high resolution diffractometer, and recommended when the manufacturer needs to be sure of the absence of a given crystalline form.

Site Badges
Baldiri Reixac 10 Barcelona, Catalonia, 08028 Spain

Get started

To request access, simply fill out the form below and we will contact you.

Password must:

• Be at least 12 characters in length

• Contain a lowercase letter (a-z)

• Contain an uppercase letter (A-Z)

• Contain a numeral (0-9)

• Contain a special character (%, $, !, @)